J. Janssen

发表

Value of estrogenic recruitment before chemotherapy: first randomized trial in primary breast cancer.

J. Foekens, J. Klijn, W. van Putten, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: a double-blind, randomized, placebo-controlled study.

J. Verweij, A. Sparreboom, R. Mathijssen, 2006, The oncologist.

First‐line nab‐paclitaxel plus carboplatin for patients with advanced non‐small cell lung cancer: Results of the NEPTUN study

B. Hackanson, M. Welslau, S. Budweiser, 2021, Cancer medicine.

Everolimus in metastatic renal cell carcinoma after failure of initial anti–VEGF therapy: final results of a noninterventional study

L. Bergmann, P. Goebell, T. Steiner, 2015, BMC Cancer.

CPT11/FA/5-FU versus ELF in chemonaive patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: A randomized phase II study.

P. Galle, A. Wein, T. Junginger, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Everolimus in Metastatic Renal Cell Carcinoma after Failure of Initial Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor (VEGFr-TKI) Therapy: Results of an Interim Analysis of a Non-Interventional Study

L. Bergmann, P. Goebell, T. Steiner, 2013, Oncology Research and Treatment.

Medication adherence with denosumab in patients with bone metastases from solid tumors treated in routine clinical settings: a retrospective study

R. Greil, I. Diel, A. Tomova, 2022, Supportive Care in Cancer.

214 Safety and efficacy of CPT11/FA/5-FU (ILF) versus ELF in previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction

P. Galle, A. Wein, J. Siebler, 2003 .

Phase II Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes

K. Pradhan, A. Verma, U. Steidl, 2019, Clinical Cancer Research.

671 Phase III study comparing AT (Adriamycin, Docetaxel) to FAC (Fluorouracil, Adriamycin, Cyclophosphamide) as first-line chemotherapy (CT) in patients with metastatic breast cancer (MBC)

C. Seynaeve, M. Bontenbal, P. Schmitz, 2003 .

Medication adherence with denosumab in patients with bone metastases from solid tumors treated in routine clinical settings: a retrospective study

R. Greil, I. Diel, A. Tomova, 2022, Supportive Care in Cancer.

Systemic therapy in metastatic renal cell carcinoma

H. Tesch, T. Gauler, K. Miller, 2016, World Journal of Urology.

Rapid infusions of human normal immunoglobulin 50 g/l are safe and well tolerated in immunodeficiencies and immune thrombocytopenia

A. Matucci, G. Spadaro, I. Quinti, 2017, International immunopharmacology.

Weekly Vinorelbine versus Docetaxel for Metastatic Breast Cancer after Failing Anthracycline Treatment

S. Rotermund, M. Steder, J. Janssen, 2008, Oncology Research and Treatment.

Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: results of a Dutch Community Setting Trial for the Clinical Trial Group of the Comprehensive Cancer Centre.

C. Seynaeve, J. Verweij, M. Bontenbal, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Everolimus in metastatic renal cell carcinoma after failure of initial anti–VEGF therapy: final results of a noninterventional study

L. Bergmann, P. Goebell, T. Steiner, 2015, BMC Cancer.

First‐line nab‐paclitaxel plus carboplatin for patients with advanced non‐small cell lung cancer: Final results of the NEPTUN study

B. Hackanson, M. Welslau, J. Riera-Knorrenschild, 2023, International journal of cancer.

Clinical efficacy and safety of regorafenib (REG) in the treatment of metastatic colorectal cancer (mCRC) in daily practice in Germany: Interim results of the prospective multicentre noninterventional RECORA study.

C. Bokemeyer, S. Fiala-Buskies, H. Schulz, 2017 .